Patents by Inventor Erkki I. Ruoslahti
Erkki I. Ruoslahti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8329859Abstract: The present invention provides a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature. The invention also provides a method of directing a moiety to tumor lymphatic vasculature in a subject by administering to the subject a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature.Type: GrantFiled: January 22, 2010Date of Patent: December 11, 2012Assignee: Sanford-Burnham Medical Research InstituteInventors: Pirjo Laakkonen, Kimmo Porkka, Jason A. Hoffman, Erkki I. Ruoslahti
-
Patent number: 7214375Abstract: The present invention provides a method for treating or arresting the progress of pathologies characterized by an accumulation of extracellular matrix components by providing an agent to suppress the activity of transforming growth factor ? (TGF-?) a peptide growth factor which is anabolic and leads to fibrosis and angiogenesis. In one embodiment, such agent is anti-TGF-? antibody. Pathologies which can be so treated include, but are not limited to, glomerulonephritis, adult respiratory distress syndrome and cirrhosis of the liver. The invention further provides a method for the diagnosis of pathologies, or incipient pathologies, which are characterized by the accumulation of extracellular matrix components in tissues by determining the levels of TGF-? in the tissues, a high level being indicative of such pathologies.Type: GrantFiled: December 2, 1994Date of Patent: May 8, 2007Assignee: La Jolla Cancer Research FoundationInventors: Wayne A. Border, Erkki I. Ruoslahti
-
Patent number: 7067619Abstract: This invention is directed to novel integrin binding peptides. These peptides bind to ?v- of ?5-containing integrins and can exhibit high binding affinity. They contain one of the following sequence motifs: RX1ETX2WX3 [SEQ ID NO:1] (especially RRETAWA [SEQ ID NO:8]); RGDGX [SEQ ID NO:2], in which X is an amino acid with a hydrophobic, aromatic side chain; the double cyclic CX1CRGDCX2C [SEQ ID NO:15]; and RLD. The peptides generally exhibit their highest binding affinity when they assume a conformationally stabilized configuration. This invention also provides methods of using these peptides.Type: GrantFiled: July 30, 1999Date of Patent: June 27, 2006Assignee: La Jolla Cancer Research FoundationInventors: Erkki I Ruoslahti, Erkki Koivunen
-
Patent number: 7030213Abstract: Novel synthetic Arg-Gly-Asp containing peptides which have high affinity and specificity for their receptors by virtue of restrictions on their stereochemical conformation. Such restrictions can be provided by cyclization, by inclusion into a constraining conformational structure such as a helix, by providing an additional chemical structure such as an amide or an enantiomer of a naturally occurring amino acid, or by other methods. In particular, there are provided cyclic peptides having increased affinity and selectivity for the certain receptors over that of linear, Arg-Gly-Asp-containing synthetic peptides.Type: GrantFiled: June 26, 2001Date of Patent: April 18, 2006Assignee: La Jolla Cancer Research InstituteInventors: Michael D. Pierschbacher, Erkki I. Ruoslahti
-
Publication number: 20040096441Abstract: The present invention provides a method of identifying a tumor homing molecule that homes to angiogenic vasculature by contacting a substantially purified NGR receptor with one or more molecules and determining specific binding of a molecule to the NGR receptor, where the presence of specific binding identifies the molecule as a tumor homing molecule that homes to angiogenic vasculature. The invention also provides a method of directing a moiety to angiogenic vasculature in a subject by administering to the subject a conjugate including a moiety linked to a tumor homing molecule that exhibits specific binding to an NGR receptor, whereby the moiety is directed to angiogenic vasculature. In addition, the invention provides a method of imaging the angiogenic vasculature of a tumor in a subject by administering to the subject a conjugate having a detectable moiety linked to a tumor homing molecule that exhibits specific binding to an NGR receptor and detecting the conjugate.Type: ApplicationFiled: October 3, 2002Publication date: May 20, 2004Applicant: THE BURNHAM INSTITUTEInventors: Erkki I. Ruoslahti, Renata Pasqualini
-
Publication number: 20040028682Abstract: The present invention provides a method for treating or arresting the progress of pathologies characterized by an accumulation of extracellular matrix components by providing an agent to suppress the activity of transforming growth factor &bgr; (TGF-&bgr;) a peptide growth factor which is anabolic and leads to fibrosis and angiogenesis. In one embodiment, such agent is anti-TGF-&bgr; antibody. Pathologies which can be so treated include, but are not limited to, glomerulonephritis, adult respiratory distress syndrome and cirrhosis of the liver. The invention further provides a method for the diagnosis of pathologies, or incipient pathologies, which are characterized by the accumulation of extracellular matrix components in tissues by determining the levels of TGF-&bgr; in the tissues, a high level being indicative of such pathologies.Type: ApplicationFiled: August 7, 2003Publication date: February 12, 2004Inventors: Wayne A. Border, Erkki I. Ruoslahti
-
Publication number: 20030143733Abstract: The peptide X-Arg-Gly-Asp-R-Y wherein X is H or at least one amino acid and Y is OH or at least one amino acid, and R is an amino acid selected from Thr or Cys, or other amino acid, having the same cell-attachment activity as fibronectin and the peptide X-Arg-Gly-Asp-Ser-Y, wherein X and Y, having said activity are disclosed.Type: ApplicationFiled: December 6, 2002Publication date: July 31, 2003Applicant: La Jolla Cancer Research FoundationInventors: Erkki I. Ruoslahti, Michael D. Pierschbacher
-
Publication number: 20030113320Abstract: The present invention provides a method of identifying a tumor homing molecule that homes to angiogenic vasculature by contacting a substantially purified NGR receptor with one or more molecules and determining specific binding of a molecule to the NGR receptor, where the presence of specific binding identifies the molecule as a tumor homing molecule that homes to angiogenic vasculature. The invention also provides a method of directing a moiety to angiogenic vasculature in a subject by administering to the subject a conjugate including a moiety linked to a tumor homing molecule that exhibits specific binding to an NGR receptor, whereby the moiety is directed to angiogenic vasculature. In addition, the invention provides a method of imaging the angiogenic vasculature of a tumor in a subject by administering to the subject a conjugate having a detectable moiety linked to a tumor homing molecule that exhibits specific binding to an NGR receptor and detecting the conjugate.Type: ApplicationFiled: October 3, 2002Publication date: June 19, 2003Applicant: THE BURNHAM INSTITUTEInventors: Erkki I. Ruoslahti, Renata Pasqualini
-
Publication number: 20030091556Abstract: The invention provides a substantially pure composition of anastellin (SEQ ID NO: 1) and fibrinogen as well as a substantially pure composition of superfibronectin and superfibrinogen. The invention also provides methods of inhibiting angiogenesis, tumor growth and metastasis by administering anastellin (SEQ ID NO: 1) alone or in combination with fibrinogen.Type: ApplicationFiled: December 3, 2001Publication date: May 15, 2003Inventors: Erkki I. Ruoslahti, Ming Yi
-
Publication number: 20030032591Abstract: The present invention provides a method of inhibiting an activity of a cell regulatory factor comprising contacting the cell regulatory factor with a purified polypeptide, wherein the polypeptide comprises the cell regulatory factor binding domain of a protein and wherein the protein is characterized by a leucine-rich repeat of about 24 amino acids. In a specific embodiment, the present invention relates to the ability of decorin, a 40,000 dalton protein that usually carries a glycosaminoglycan chain, to bind TGF-&bgr;. The invention also provides a novel cell regulatory factor designated MRF. Also provided are methods of identifying, detecting and purifying cell regulatory factors and proteins which bind and affect the activity of cell regulatory factors. The present invention further relates to methods for the prevention or reduction of scarring by administering decorin or a functional equivalent of decorin to a wound.Type: ApplicationFiled: August 21, 2001Publication date: February 13, 2003Applicant: The Burnham InstituteInventors: Erkki I. Ruoslahti, Michael T. Longaker, David J. Whitby, John R. Harper, Michael D. Pierschbacher, Wayne A. Border
-
Patent number: 6509314Abstract: The present invention relates to methods of preventing or reducing scarring in a wound area by administering decorin or biglycan to the wound.Type: GrantFiled: June 13, 1994Date of Patent: January 21, 2003Assignee: The Burnham InstituteInventors: Erkki I. Ruoslahti, Wayne A. Border
-
Patent number: 6436900Abstract: The present invention provides methods of treating pathologies using Decorin.Type: GrantFiled: June 2, 1995Date of Patent: August 20, 2002Assignee: La Jolla Cancer Research FoundationInventors: Erkki I. Ruoslahti, Yu Yamaguchi
-
Publication number: 20020028913Abstract: Novel synthetic Arg-Gly-Asp containing peptides which have high affinity and specificity for their receptors by virtue of restrictions on their stereochemical conformation. Such restrictions can be provided by cyclization, by inclusion into a constraining conformational structure such as a helix, by providing an additional chemical structure such as an amide or an enantiomer of a naturally occurring amino acid, or by other methods. In particular, there are provided cyclic peptides having increased affinity and selectivity for the certain receptors over that of linear, Arg-Gly-Asp-containing synthetic peptides.Type: ApplicationFiled: June 26, 2001Publication date: March 7, 2002Applicant: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, Erkki I. Ruoslahti
-
Patent number: 6353090Abstract: Novel synthetic Arg-Gly-Asp containing peptides which have high affinity and specificity for their receptors by virtue of restrictions on their stereochemical conformation. Such restrictions can be provided by cyclization, by inclusion into a constraining conformational structure such as a helix, by providing an additional chemical structure such as an amide or an enantiomer of a naturally occurring amino acid, or by other methods. In particular, there are provided cyclic peptides having increased affinity and selectivity for the certain receptors over that of linear, Arg-Gly-Asp-containing synthetic peptides.Type: GrantFiled: August 4, 1999Date of Patent: March 5, 2002Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, Erkki I. Ruoslahti
-
Publication number: 20010046498Abstract: The present invention provides a chimeric prostate-homing peptide with pro-apoptotic activity. In a preferred embodiment, the chimeric prostate-homing pro-apoptotic peptide contains the sequence SMSIARL-GG-D(KLAKLAK)2. Methods of using such chimeric peptides for treating patients having prostate cancer also are provided.Type: ApplicationFiled: January 17, 2001Publication date: November 29, 2001Inventors: Erkki I. Ruoslahti, Renata Pasqualini, Wadih Arap, Dale E. Bredesen, H. Michael Ellerby
-
Patent number: 6277812Abstract: The present invention provides a method of inhibiting an activity of a cell regulatory factor comprising contacting the cell regulatory factor with a purified polypeptide, wherein the polypeptide comprises the cell regulatory factor binding domain of a protein and wherein the protein is characterized by a leucine-rich repeat of about 24 amino acids. In a specific embodiment, the present invention relates to the ability of decorin, a 40,000 dalton protein that usually carries a glycosaminoglycan chain, to bind TGF-&bgr;. The invention also provides a novel cell regulatory factor designated MRF. Also provided are methods of identifying, detecting and purifying cell regulatory factors and proteins which bind and affect the activity of cell regulatory factors. The present invention further relates to methods for the prevention or reduction of scarring by administering decorin or a functional equivalent of decorin to a wound.Type: GrantFiled: June 2, 1995Date of Patent: August 21, 2001Assignee: The Burnham InstituteInventors: Erkki I. Ruoslahti, Yu Yamaguchi
-
Patent number: 6046162Abstract: A method of suppressing cell proliferation of a mammalian cell by contacting the cell with decorin.Type: GrantFiled: June 2, 1995Date of Patent: April 4, 2000Assignee: La Jolla Cancer Research FoundationInventors: Erkki I. Ruoslahti, Yu Yamaguchi
-
Patent number: 6020460Abstract: Novel synthetic Arg-Gly-Asp-containing peptides which have high affinity and specificity for their receptors by virtue of restrictions on their stereochemical conformation. Such restrictions can be provided by cyclization, by inclusion into a constraining conformational structure such as a helix, by providing an additional chemical structure such as an amide or an enantiomer of a naturally occuring amino acid, or by other methods. In particular, there is provided a cyclic peptide having increased affinity and selectivity for the vitronectin receptor over that of linear, Arg-Gly-Asp-containing synthetic peptides.Type: GrantFiled: December 14, 1994Date of Patent: February 1, 2000Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, Erkki I. Ruoslahti
-
Patent number: 5985827Abstract: Novel synthetic Arg-Gly-Asp containing peptides which have high affinity and specificity for their receptors by virtue of restrictions on their stereochemical conformation. Such restrictions can be provided by cyclization, by inclusion into a constraining conformational structure such as a helix, by providing an additional chemical structure such as an amide or an enantiomer of a naturally occurring amino acid, or by other methods. In particular, there are provided cyclic peptides having increased affinity and selectivity for the certain receptors over that of linear, Arg-Gly-Asp-containing synthetic peptides.Type: GrantFiled: June 2, 1995Date of Patent: November 16, 1999Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, Erkki I. Ruoslahti
-
Patent number: 5981468Abstract: Novel synthetic Arg-Gly-Asp containing peptides which have high affinity and specificity for their receptors by virtue of restrictions on their stereochemical conformation. Such restrictions can be provided by cyclization, by inclusion into a constraining conformational structure such as a helix, by providing an additional chemical structure such as an amide or an enantiomer of a naturally occurring amino acid, or by other methods. In particular, there are provided cyclic peptides having increased affinity and selectivity for the certain receptors over that of linear, Arg-Gly-Asp-containing synthetic peptides.Type: GrantFiled: June 2, 1995Date of Patent: November 9, 1999Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, Erkki I. Ruoslahti